US cancer and infectious disease specialist Inovio Pharmaceuticals has appointed two specialists in vaccines and cancer immunotherapy, Dr Thomas Edgington and Dr Philip Greenberg, to its advisory board.
Dr Edgington is currently working as an Emeritus Professor at the Scripps Research Institute, while Dr Greenberg is a Professor of Medicine (Oncology) and Immunology at the University of Washington.
Dr Joseph Kim, President and CEO of Inovio, said that the company is developing a new generation of DNA vaccines to treat “many cancers and difficult infectious diseases. Drs Edgington and Greenberg share our vision and we are honoured to have these two renowned medical research leaders join us in this important endeavour.”
Dr Edgington said: “I am pleased to help guide Inovio’s scientific team as it continues to target difficult diseases and advance new preventive and therapeutic vaccines.”
Pennsylvania-based Inovio Pharmaceuticals manufactures and distributes DNA vaccines to prevent or treat cancers and chronic infectious diseases.